ME01344B - Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznosti - Google Patents
Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznostiInfo
- Publication number
- ME01344B ME01344B MEP-2011-166A MEP16611A ME01344B ME 01344 B ME01344 B ME 01344B ME P16611 A MEP16611 A ME P16611A ME 01344 B ME01344 B ME 01344B
- Authority
- ME
- Montenegro
- Prior art keywords
- benzo
- dihydro
- group
- dioxynyl
- lower alkyl
- Prior art date
Links
- -1 heterocycle sulfamide derivatives Chemical class 0.000 title claims 6
- 208000008589 Obesity Diseases 0.000 title claims 4
- 235000020824 obesity Nutrition 0.000 title claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- KXSAIQPPGSSNKX-ZETCQYMHSA-N (2s)-6-chloro-2-[(sulfamoylamino)methyl]-2,3-dihydro-1,4-benzodioxine Chemical compound ClC1=CC=C2O[C@@H](CNS(=O)(=O)N)COC2=C1 KXSAIQPPGSSNKX-ZETCQYMHSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003880 negative regulation of appetite Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1.Spoj formule (I): ili njegova farmaceutski prihvatljiva sol za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita naznačen time da: R1 iR2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; pri čemu b je cijeli broj od 0 do 4; i gdje a je cijeli broj od 0 do 2; svaki R5 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada je ili tada a je 1.
2.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; gdje je cijeli broj od 0 do 2; gdje c je cijeli broj od 0 do 1; svaki R5 je Nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada ili tada a je 1.
3.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 2, naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koju čine vodik i niži alkil; R1 je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; pri čemu bje cijeli broj od 0 do 2; i pri čemu c je 0; svaki R6 je nezavisno odabran iz skupine koja sadrži halogen i niži alkil; pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika pod uvjetom da kada tada a je 1.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 3 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i niži alkil; R4 je odabran iz skupine koju sačinjavaju vodik i metil; a je cijeli broj od 1 do 2: je odabran iz skupine koju sačinjavaju 2-(2,3-dihidrobenzo[l,4]dioksinil), 2- (benzo[l,3]dioksolil), 2-(3,4-dihidro-2H-benzo[l,4]dioksepinil), 2-(8-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(6-fluoro-2,3-dihidro-benzo[l,4]dioksinil), 2- (kromanil), 2-(6-fluoro-2,3-dihidro-benzo[ 1,4]dioksinil), 2-(7-kloro-2,3-dihidro- benzo[l,4]dioksinil), 2-(6-kloro-benzo[l,3]dioksolil), 2-(7-metil-2,3-dihidro- benzo[ 1,4]dioksinil), 2-(5-kloro-2,3-dihidro-benzo[ 1,4]dioksinil), 2-(6-bromo-2,3- dihidro-benzo[l,4]dioksinil), 2-(6,7-dikloro-2,3-dihidro-benzo[l,4]dioksinil), 2-(8- kloro-2,3-dihidro-benzo[l,4]dioksinil), 2-(2,3-dihidro-nafto[2,3-b][l,4]dioksinil) i 2- (4-metil-benzo[l,3]dioksolil);pri čemu "niži alkil" se odnosi na spoj ugljikovog lanca sa 1-4 atoma ugljika, pod uvjetom da kada je 2-(3,4-dihidro-2H-benzo[l,4]dioksepinil), tada a je 1.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 4 naznačen time da: R1 i R2 su svaki nezavisno odabrani iz skupine koja sadrži vodik i metil; R4 je odabran iz skupine koja sadrži vodik i metil; a je cijeli broj od 1 do 2; je odabran iz skupine koju sačinjavaju 2-benzo[l,3]dioksolil), 2-(2,3-dihidro- benzo[l,4]dioksinil), 2-(6-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(7-kloro-2,3- dihidro-benzo[l,4]dioksinil), 2-(7-metil-2,3-dihidro-benzo[l,4]dioksinil), 2-(6-bromo- 2,3-dihidrobenzo[l,4]dioksinil) i 2-(6,7-dikloro-2,3-dihidro-benzo[l,4]dioksinil).
6.Spoj prema zahtjevu 1, naznačen time daje spoj prema formuli (I) odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidrobenzo[l,4]dioksin-2-ilmetil)-sulfamido; i njegove farmaceutski prihvatljive soli.
7.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzo[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod liječenja pretilosti.
8.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzo[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod poticanja gubitka težine.
9.Spoj naznačen time da je odabran iz skupine koju čine (2S)-(-)-N-(6-kloro-2,3-dihidro- benzol[l,4]dioksin-2-ilmetil)-sulfamid; i njegove farmaceutski prihvatljive soli za uporabu kod suzbijanja apetita.
10.Spoj formule (II) ili njegova farmaceutski prihvatljiva sol naznačen time daje za upotrebu kod liječenja pretilosti, poticanje gubitka težine ili suzbijanje apetita.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75149905P | 2005-12-19 | 2005-12-19 | |
| US11/611,938 US8492431B2 (en) | 2005-12-19 | 2006-12-18 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| EP06847860A EP1968574B9 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| PCT/US2006/048681 WO2007075833A2 (en) | 2005-12-19 | 2006-12-19 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01344B true ME01344B (me) | 2013-12-20 |
Family
ID=37992995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-166A ME01344B (me) | 2005-12-19 | 2006-12-19 | Upotreba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje gojaznosti |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8492431B2 (me) |
| EP (1) | EP1968574B9 (me) |
| JP (1) | JP5190378B2 (me) |
| KR (1) | KR101363308B1 (me) |
| CN (1) | CN101365442B (me) |
| AR (1) | AR058389A1 (me) |
| AT (1) | ATE519484T1 (me) |
| AU (1) | AU2006331637B2 (me) |
| BR (1) | BRPI0620019A2 (me) |
| CA (1) | CA2634093C (me) |
| CR (1) | CR10164A (me) |
| CY (1) | CY1112357T1 (me) |
| DK (1) | DK1968574T3 (me) |
| EA (1) | EA016560B1 (me) |
| ES (1) | ES2369761T3 (me) |
| HR (1) | HRP20110726T2 (me) |
| IL (1) | IL192107A (me) |
| ME (1) | ME01344B (me) |
| MY (1) | MY145823A (me) |
| NO (1) | NO20083006L (me) |
| NZ (1) | NZ568960A (me) |
| PE (1) | PE20070813A1 (me) |
| PL (1) | PL1968574T3 (me) |
| PT (1) | PT1968574E (me) |
| RS (1) | RS52044B (me) |
| SI (1) | SI1968574T1 (me) |
| SV (1) | SV2008002952A (me) |
| UY (1) | UY30033A1 (me) |
| WO (1) | WO2007075833A2 (me) |
| ZA (1) | ZA200806279B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| BRPI0610864A2 (pt) * | 2005-05-20 | 2010-08-03 | Janssen Pharmaceutica Nv | processo para preparação de derivados de sulfamida |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
| JP2011519839A (ja) * | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
| DK2271638T3 (da) * | 2008-04-29 | 2011-11-28 | Nsab Af Neurosearch Sweden Ab | Modulatorer af dopaminneurotransmission |
| WO2009133107A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| PE20110060A1 (es) | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
| US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| KR20140082762A (ko) | 2011-09-29 | 2014-07-02 | 얀센 파마슈티카 엔.브이. | 설파미드 유도체의 개선된 제조 방법 |
| CA2850513A1 (en) | 2011-09-29 | 2013-04-04 | Janssen Pharmaceutica Nv | Process for the preparation of sulfamide derivatives |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2527861A (en) | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
| BE636655A (me) | 1962-09-14 | |||
| DE1211166B (de) | 1962-11-20 | 1966-02-24 | Ciba Geigy | Verfahren zur Herstellung neuer Sulfamide |
| US3320314A (en) | 1964-01-22 | 1967-05-16 | Sandoz Ag | Chlorobenzyl sulfamides |
| US3318952A (en) | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
| US3383414A (en) | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
| DE1542785A1 (de) | 1965-07-24 | 1970-05-06 | Bayer Ag | Insekten- und milbenabweisende Mittel |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3621096A (en) | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
| DE2022370A1 (de) | 1970-05-08 | 1971-12-02 | Bayer Ag | N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung |
| US5212326A (en) | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
| FR2479825A1 (fr) | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US5273993A (en) | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
| US5194446A (en) | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
| US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
| US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
| GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| IL103172A (en) | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
| US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5258402A (en) | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| AU695336B2 (en) | 1993-12-23 | 1998-08-13 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| US5731348A (en) | 1995-02-15 | 1998-03-24 | Bearsden Bio, Inc. | Alkylcarboxy amino acids-modulators of the kainate receptor |
| JP3235448B2 (ja) | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | １，４−ベンゾジオキサン誘導体の製法 |
| US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| WO1997019919A1 (en) | 1995-11-30 | 1997-06-05 | C & C Research Laboratories | Sulfamide derivatives |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| WO1997035584A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
| US5753693A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| WO1998000124A1 (en) | 1996-06-28 | 1998-01-08 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
| US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| SK284305B6 (sk) | 1996-06-28 | 2005-01-03 | Ortho-Mcneil Pharmaceutical, Inc. | Liečivo na liečbu obezity |
| SI9720059B (sl) | 1996-08-14 | 2011-11-30 | Searle & Co | Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida |
| CA2264182A1 (en) | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US20020015713A1 (en) | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| US5935933A (en) | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
| US5760007A (en) | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| DE69827149T2 (de) | 1997-08-15 | 2006-03-09 | Fairbanks, Carolyn Ann, Rochester | Agmatin für die behandlung neuropathischer schmerzen |
| GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
| UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
| DK72798A (da) | 1998-05-28 | 1998-05-28 | Novo Nordisk As | Treatment of GABA-uptake related disorders |
| WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| ES2228465T3 (es) | 1999-01-19 | 2005-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes. |
| AR022321A1 (es) | 1999-01-21 | 2002-09-04 | Ortho Mcneil Pharm Inc | Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada |
| ES2238999T3 (es) | 1999-02-24 | 2005-09-16 | University Of Cincinnati | Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos. |
| AU3898700A (en) | 1999-03-15 | 2000-10-04 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| MXPA01010217A (es) | 1999-04-08 | 2005-09-08 | Johnson & Johnson | Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos. |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| JP2003530300A (ja) | 1999-04-08 | 2003-10-14 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 体重低下を維持することに有用な抗痙攣薬誘導体 |
| US6191163B1 (en) | 1999-04-08 | 2001-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
| DK1181012T3 (da) | 1999-05-04 | 2005-01-24 | Keith R Edwards | Intravenöst valproat til akut behandling af migrænehovedpine |
| WO2000076493A1 (en) | 1999-06-14 | 2000-12-21 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
| IL148019A0 (en) | 1999-08-20 | 2002-09-12 | Ortho Mcneil Pharm Inc | Composition comprising a tramadol material and an anticonvulsant drug |
| FR2803848B1 (fr) | 2000-01-19 | 2002-02-15 | Adir | Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6322503B1 (en) | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| DK1309324T3 (da) | 2000-07-07 | 2006-06-12 | Ortho Mcneil Pharm Inc | Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X |
| DE10035227A1 (de) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| AU2001280865A1 (en) | 2000-08-02 | 2002-02-13 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| US7256184B2 (en) | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
| US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| WO2002096424A1 (en) | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| RU2246727C2 (ru) | 2003-02-12 | 2005-02-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) | Способ диагностики доклинической стадии эпилепсии |
| RU2226357C1 (ru) | 2003-02-12 | 2004-04-10 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева | Способ диагностики эпилепсии у пациентов с доклинической стадией болезни |
| US7425631B2 (en) | 2003-04-10 | 2008-09-16 | Amgen Inc. | Compounds and methods of use |
| JP4373343B2 (ja) | 2003-04-16 | 2009-11-25 | スミスクライン・ビーチャム・コーポレイション | ペプチドデホルミラーゼ阻害剤 |
| WO2004093912A1 (ja) | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | 好中球性炎症疾患の予防および／または治療剤 |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US6949518B1 (en) | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
| CN1845914A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 用于治疗眼压过高的眼用组合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| TW200612905A (en) | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| US7569604B2 (en) | 2004-06-22 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives for modulation of calcium channels |
| PL1781639T3 (pl) | 2004-07-28 | 2012-07-31 | Janssen Pharmaceutica Nv | Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej |
| PE20060500A1 (es) | 2004-08-24 | 2006-07-13 | Janssen Pharmaceutica Nv | Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes |
| US20060276528A1 (en) | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| RU2007139543A (ru) | 2005-04-22 | 2009-05-27 | Вайет (Us) | Производные бензодиоксана и бензодиоксолана и их применение |
| BRPI0610864A2 (pt) | 2005-05-20 | 2010-08-03 | Janssen Pharmaceutica Nv | processo para preparação de derivados de sulfamida |
| US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| TW200812574A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| WO2008061903A1 (en) | 2006-11-22 | 2008-05-29 | Agfa Healthcate Inc. | Method and system for client / server distributed image processing |
| CA2711466A1 (en) | 2008-01-07 | 2009-07-16 | Janssen Pharmaceutica N.V. | Process for the preparation of sulfamide derivatives |
| US20090247617A1 (en) | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| US20090247618A1 (en) | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
| PE20110060A1 (es) | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
-
2006
- 2006-12-18 AR ARP060105591A patent/AR058389A1/es not_active Application Discontinuation
- 2006-12-18 US US11/611,938 patent/US8492431B2/en not_active Expired - Fee Related
- 2006-12-19 KR KR1020087017531A patent/KR101363308B1/ko not_active Expired - Fee Related
- 2006-12-19 PE PE2006001639A patent/PE20070813A1/es not_active Application Discontinuation
- 2006-12-19 ME MEP-2011-166A patent/ME01344B/me unknown
- 2006-12-19 CN CN2006800524528A patent/CN101365442B/zh not_active Expired - Fee Related
- 2006-12-19 WO PCT/US2006/048681 patent/WO2007075833A2/en not_active Ceased
- 2006-12-19 JP JP2008547519A patent/JP5190378B2/ja not_active Expired - Fee Related
- 2006-12-19 UY UY30033A patent/UY30033A1/es unknown
- 2006-12-19 EP EP06847860A patent/EP1968574B9/en active Active
- 2006-12-19 AU AU2006331637A patent/AU2006331637B2/en not_active Ceased
- 2006-12-19 PT PT06847860T patent/PT1968574E/pt unknown
- 2006-12-19 RS RS20110496A patent/RS52044B/sr unknown
- 2006-12-19 DK DK06847860.1T patent/DK1968574T3/da active
- 2006-12-19 HR HRP20110726TT patent/HRP20110726T2/hr unknown
- 2006-12-19 PL PL06847860T patent/PL1968574T3/pl unknown
- 2006-12-19 SI SI200631151T patent/SI1968574T1/sl unknown
- 2006-12-19 EA EA200870093A patent/EA016560B1/ru not_active IP Right Cessation
- 2006-12-19 MY MYPI20082188A patent/MY145823A/en unknown
- 2006-12-19 ES ES06847860T patent/ES2369761T3/es active Active
- 2006-12-19 BR BRPI0620019-2A patent/BRPI0620019A2/pt not_active IP Right Cessation
- 2006-12-19 CA CA2634093A patent/CA2634093C/en not_active Expired - Fee Related
- 2006-12-19 NZ NZ568960A patent/NZ568960A/en not_active IP Right Cessation
- 2006-12-19 AT AT06847860T patent/ATE519484T1/de active
-
2008
- 2008-06-12 IL IL192107A patent/IL192107A/en not_active IP Right Cessation
- 2008-06-19 SV SV2008002952A patent/SV2008002952A/es unknown
- 2008-07-03 NO NO20083006A patent/NO20083006L/no not_active Application Discontinuation
- 2008-07-18 ZA ZA200806279A patent/ZA200806279B/xx unknown
- 2008-07-21 CR CR10164A patent/CR10164A/es not_active Application Discontinuation
-
2011
- 2011-11-09 CY CY20111101079T patent/CY1112357T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110726T2 (hr) | Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti | |
| HRP20100007T1 (hr) | Upotreba benzo-spojenih heterocikličkih derivata sulfamida za liječenje boli | |
| HRP20120018T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida kao neurozaštitnih sredstava | |
| HRP20110384T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja | |
| HRP20110008T1 (hr) | Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za smanjenje razine masnoća i šećera u krvi | |
| PE20080716A1 (es) | Coterapia constituida por un derivado de heterociclosulfamida benzofusionado y uno o varios agentes anticonvulsivantes y/o antilepticos | |
| JP2009520036A5 (me) | ||
| JP2009520035A5 (me) | ||
| ES2573844T3 (es) | Derivados de sulfamidas y sulfamatos para el tratamiento de epilepsia y trastornos relacionados | |
| JP2009520030A5 (me) | ||
| AR063081A1 (es) | Derivados de 3- aza- biciclo [3.1.0] hexano y su uso para la preparacion de medicamentos | |
| PL2176252T3 (pl) | 2,3-dihydrobenzo[1,4]dioksyn-2-ylometylopochodne jako antagoniści receptora alfa2c do zastosowania w leczeniu chorób obwodowego i ośrodkowego układu nerwowego | |
| AR110945A1 (es) | Suplemento de alimento para animales y composición que comprende dicho suplemento | |
| BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
| RU2007133167A (ru) | Препарат на основе смеси флавоноидов со свободным в-циклом и флаванов, как терапевтический агент | |
| BRPI0418082A (pt) | antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a | |
| AR014948A1 (es) | Compuestos macrolidos, composiciones, su uso para la manufactura de medicamentos y metodo para prepararlos. | |
| BRPI0915890A2 (pt) | forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida | |
| RU96120173A (ru) | Бензотиофен, бензофуран и индолтиазепиноны, оксазепиноны и диазепиноны в качестве ингибиторов клеточной адгезии и в качестве ингибиторов вича | |
| AR104121A1 (es) | DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA | |
| KR900003175A (ko) | 벤조피라놀 유도체 | |
| DE69507652D1 (de) | Alkylaminoindanverbindungen, Verfahren zu deren Herstellung und diese enthaltenden pharmazeutische Zusammenstellungen | |
| AR016386A1 (es) | D- o l-lixofuranosil benzimidazoles composicion que los contiene, procedimiento para su preparacion y su uso para la manufactura de un medicamento | |
| RU2004114843A (ru) | Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни | |
| EA200100564A1 (ru) | Препарат, снижающий выделение пролактина |